Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS...
-
Upload
sara-carson -
Category
Documents
-
view
217 -
download
0
Transcript of Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS...
![Page 1: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/1.jpg)
Medication Assisted Treatment (MAT)
in Pregnant Women
Susan F. Neshin, M.D.
Medical Director
JSAS Healthcare, Inc.
Asbury Park, NJ
E-mail: [email protected]
![Page 2: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/2.jpg)
Overview of Presentation
• What is MAT?
• Rationale for MAT
• Importance of Dose Adequacy
• Impact of MAT
• The Medications
• Women’s Issues/PREGNANCY
• Addressing Stigma
![Page 3: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/3.jpg)
What is MAT?
• MAT=Medication Assisted Treatment in context of substance abuse treatment
• EUPHEMISM for opioid maintenance therapy– Methadone– Buprenorphine
• Broaden definition– Naltrexone– Medication for other drug dependencies– Medication in the treatment of chronic disease
![Page 4: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/4.jpg)
Medications Development Division
• Branch of National Institute on Drug Abuse (NIDA)
• Developing new medications
• Addiction as a brain disease
• Drug craving as a physiologic phenomenon
![Page 5: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/5.jpg)
Rationale for MAT/OMTFor Chronic Opioid Dependence
• Dole’s concept of metabolic derangement
• Current concept of neuronal adaptations to repeated exposures of the drug
• Pre-existing vulnerability and/or consequence of opioid use
• Corrective, not curative
![Page 6: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/6.jpg)
On/Off - Non-Tolerant Drug StatesOn/Off - Non-Tolerant Drug StatesM
oo
d/E
ffe
ct
Sc
ale “ON”
Drug Effect
“OFF”
No Drug Effect;
“Normal”
Overdose
Intoxication
Euphoria
“Normophoria”
Dysphoria
Opioid Maintenance Pharmacotherapy - A Course for Clinicians6
![Page 7: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/7.jpg)
Do
se R
esp
on
se
Time
“Loaded” “High”
Normal Range“Comfort Zone”
“Sick”
Heroin Simulated 24 Hr. Dose/Response
With established heroin tolerance/dependence
0 hrs.
24 hrs.
“Abnormal Normality”
Subjective w/d
Objective w/d
Opioid Maintenance Pharmacotherapy - A Course for Clinicians7
![Page 8: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/8.jpg)
Do
se R
esp
on
se
Time
“Loaded” “High”
Normal Range“Comfort Zone”
“Sick”
Methadone Simulated 24 Hr. Dose/ResponseAt steady-state in tolerant patient
0 hrs.
24 hrs.
“Abnormal Normality”
Subjective w/d
Objective w/d
Opioid Maintenance Pharmacotherapy - A Course for Clinicians
8
![Page 9: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/9.jpg)
Goals for Pharmacotherapy
• Prevention or reduction of withdrawal symptoms
• Prevention or reduction of drug craving
• Prevention of relapse to use of addictive drug
• Restoration to or toward normalcy of any physiological function disrupted by drug addiction
![Page 10: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/10.jpg)
Importance of
Dose Adequacy!
![Page 11: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/11.jpg)
Recent Heroin Use by Current Methadone Dose
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70 80 90 100
Current Methadone Dose mg/day
% H
ero
in U
se
J. C. Ball, November 18, 1988
![Page 12: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/12.jpg)
Retention in Treatment Relative to Dose
0 20 40 60 80 100
80 + mg
60-79 mg
< 60 mg
Adapted from Caplehorn & Bell - The Medical Journal of Australia
![Page 13: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/13.jpg)
Impact of Maintenance Treatment
• Reduction death rates (Grondblah, ‘90)
• Reduction IVDU (Ball & Ross, ‘91)
• Reduction crime days (Ball & Ross)
• Reduction rate of HIV seroconversion
(Bourne, ‘88; Novick ‘90,; Metzger ‘93)
• Reduction relapse to IVDU (Ball & Ross)
• Improved employment, health, & social
function
![Page 14: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/14.jpg)
DEATH RATES IN TREATED AND UNTREATED HEROIN
ADDICTS
0
1
2
3
4
5
6
7
8
MMT VOL DC TX INVOL DC TX UNTREATED
OBSERVEDEXPECTED
Slide data courtesy of Frank Vocci, MD, NIDA - Reference: Grondblah, L. et al.
ACTA PSCHIATR SCAND, P. 223-227, 1990
% A
nn
ua
l De
ath
Rat
es
14
![Page 15: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/15.jpg)
Impact of MMT on IV Drug Use for 388 Male MMT Patients in 6 Programs
PE
RC
EN
T I
V U
SE
RS
0
100
LA
ST
AD
DIC
TIO
N P
ER
IOD
AD
MIS
SIO
N
100%
81.4%
Pre- | 1st Year | 2nd Year | 3rd Year | 4th Year Admission
*
*
63.3%
41.7%
28.9%
Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991
![Page 16: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/16.jpg)
Crime among 491 patients before and during MMT at 6 programs
0
50
100
150
200
250
300
A B C D E F
Before TX
During TX
Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991
Cri
me
Day
s P
er Y
ear
![Page 17: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/17.jpg)
HIV CONVERSION IN TREATMENT
0%
5%
10%
15%
20%
25%
In Tx (N=95) Partial Tx(N=45)
No Tx (N=55)
Tx Status
18 month HIV conversion by treatment retentionSource: Metzger, D. et. al. J of AIDS 6:1993. p.1053
![Page 18: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/18.jpg)
OMT as Treatment of Choicefor Chronic Relapsing Opioid
Addict
• Concept of “prolonged abstinence”
– Hyper-reactivity to stress
– Dysphoria/craving increase vulnerability to relapse
![Page 19: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/19.jpg)
Relapse to IV drug use after MMT105 male patients who left treatment
28.9
45.5
57.6
72.2
82.1
0
20
40
60
80
100
IN 1 to 3 4 to 6 7 to 9 10 to 12
Pe
rce
nt
IV U
se
rs
Treatment Months Since Stopping Treatment
Adapted from Ball & Ross - The Effectiveness of Methadone Maintenance Treatment, 1991
![Page 20: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/20.jpg)
The Medications
• Methadone
– Long-acting full opioid agonist
– Orally effective
– Can be taken once a day
– Prescribed and dispensed at licensed OTPs
![Page 21: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/21.jpg)
The Medications• Buprenorphine
– Approved by FDA in October, 2002– Result of DATA 2000– Long-acting partial opioid agonist– Sublingually effective– Can be taken once a day or less frequently– Prescribed by private practitioner with
waiver
![Page 22: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/22.jpg)
The Medications
• Naltrexone
– Long-acting opioid antagonist
– Orally effective
– Can be taken once a day or less frequently
– Benefits subgroups of opioid addicts
![Page 23: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/23.jpg)
Addiction as a Biopsychosocial Disease
• OMT addresses the biological aspect
• Psychosocial aspects addressed
– Substance abuse counseling
– Mental health treatment
– Support and self-help groups
• Accreditation standards– Should improve treatment– Eliminate “gas and go” model
![Page 24: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/24.jpg)
Women’s Issues
• Higher levels of dual diagnosis than men
• Childcare
• Transportation
• Domestic Violence
• Educational/Vocational
• Financial
• Pregnancy
![Page 25: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/25.jpg)
How to Address Women’s Issues
• Accreditation standards
• Variable levels of resources
• Women’s Set-Aside funds
• One-stop shopping
![Page 26: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/26.jpg)
Dual Diagnosis
• Depression/mood disorders
• Anxiety disorders/PTSD
• Eating disorders
• Symptoms
– Guilt and shame
– Low self esteem
![Page 27: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/27.jpg)
Dual Diagnosis
• Train counseling staff
• Availability of therapist
• Availability of psychiatrist
• Staff with expertise in “survivor” issues
– Lifetime prevalence of drug abuse > 4 times greater in women who report history of sexual assault
• Support/therapy groups
![Page 28: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/28.jpg)
Childcare Issues
• Most women in treatment are of childbearing age
• Children as barrier to treatment
• Services to address
– Children welcome
– On-site child care
– Parenting classes
![Page 29: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/29.jpg)
Transportation Issues• Lack of transportation as barrier to treatment• Clinics in “out of the way” areas• Services to address
– Use of medical transportation for Medicaid patients– Site program close to public transportation– Give “take-homes” when earned– Van service– Home medication/family member pick-up for
homebound patients
![Page 30: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/30.jpg)
Domestic Violence
• Train staff
• Facilitate referral to shelter when appropriate
• Support/therapy group
![Page 31: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/31.jpg)
Educational/Vocational Issues
• Most women in treatment are “undereducated” and “underemployed”
• Services to address:
– Train staff about community resources/state-funded programs
– On-site vocational counselor
– Address “sex for drugs” issues
![Page 32: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/32.jpg)
Financial Issues• Treatment is expensive• Proprietary vs. publicly-funded non-profit programs• Services to address patient issues
– Accept Medicaid as payment– Allow for reduced fee/indigency– Counsel on budgeting– Counselor referrals to/interventions with local
service agencies
![Page 33: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/33.jpg)
Financial Issues
• Program issues
– Fund raising
– Lobbying for higher state/federal funding
![Page 34: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/34.jpg)
Considerations for Treatment of Pregnant Opiate Addict
• Tolerance level
• Chronicity of use
• Route of administration
• Pregnancy history
• Motivational level
• Recovery environment
• Ideal vs. Reality
![Page 35: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/35.jpg)
OMT/MAT as Standard of Care
• Steady levels of opiates normalize neuroendocrine functioning and prevent fetal distress
• Decreases rates of pregnancy complications, e.g. miscarriage, stillbirth, IUGR, abruptio placenta, infection, hemorrhage
• Improves prenatal care• Allows for psychosocial interventions to improve
level of functioning
![Page 36: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/36.jpg)
Perinatal Addiction
• Importance of pregnancy testing at intake
• Priority admission should be given to pregnant patients
• Family planning as counseling issue with periodic pregnancy testing, especially during medically supervised withdrawal
• Dose of methadone should be individually determined and adequate to control craving and prevent withdrawal syndrome
![Page 37: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/37.jpg)
Perinatal Addiction
• MMT patients who become pregnant should be continued at established dose. A mid-trimester reduction may be appropriate in anticipation of 3rd trimester dose increase.
• Altered pharmacokinetics during 3rd trimester often require dose increases and often a split dose to “flatten the curve” and improve maternal and fetal stability.
![Page 38: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/38.jpg)
Perinatal Addiction
• There is no consistent correlation between maternal methadone dose and the severity of neonatal withdrawal syndrome (Stimmel et al., 1982).
• Protocols are available for scoring signs of opioid withdrawal to guide the appropriate use of medications to facilitate a safe and comfortable withdrawal of the passively addicted neonate (Finnegan, 1985).
![Page 39: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/39.jpg)
Perinatal Addiction
• Breast-feeding may be encouraged during MMT - if not otherwise contraindicated (Kaltenbach, 1992).
• Multiple longitudinal studies find that methadone-exposed infants score well within the normal range of development (Kaltenbach, 1992).
![Page 40: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/40.jpg)
Perinatal Addiction
• Obstacles and barriers to MMT must be removed for the pregnant patients.
• More research is needed on innovative models of treatment including medically supervised withdrawal during pregnancy with residential care, intensive relapse prevention and monitoring, high-risk prenatal care. When appropriate hospitals, clinics and individual obstetricians could provide methadone maintenance.
![Page 41: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/41.jpg)
Withdrawal during Pregnancy
Rarely appropriate during pregnancy (ASAM 1990)
• Same recidivism as non-pregnant opioid addicts
• Slow withdrawal between 14 and 32 week
Patient lives in an area where MM is not available.
Patient refuses to be placed on MM.
Patient has been stable and requests withdrawal prior to delivery.
![Page 42: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/42.jpg)
Withdrawal during Pregnancy
• No harm reduction with OMT
• Patient has been so disruptive to the treatment setting that the treatment of other patients is jeopardized, necessitating the removal of the patient from the program.
![Page 43: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/43.jpg)
Pregnancy
Comprehensive OMT with adequate prenatal care can reduce the incidence of obstetrical and fetal complications, in utero growth retardation, and neonatal morbidity and mortality (Finnegan, 1991).
![Page 44: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/44.jpg)
Model Perinatal Program
• On-site prenatal care
• On-site well-baby care
• On-site child care
• Educational groups
– Pregnancy/medical issues
– Methadone and pregnancy
– Effects of drugs of abuse, including alcohol and nicotine, on fetus
![Page 45: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/45.jpg)
![Page 46: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/46.jpg)
![Page 47: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/47.jpg)
![Page 48: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/48.jpg)
![Page 49: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/49.jpg)
![Page 50: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/50.jpg)
![Page 51: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/51.jpg)
![Page 52: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/52.jpg)
![Page 53: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/53.jpg)
Model Perinatal Program
• Educational groups--continued
– Nutrition
– Baby care
– Parenting skills--include fathers
– Contraception/Family Planning
– Domestic Violence
![Page 54: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/54.jpg)
Model Perinatal Program
• Counseling on pregnancy termination and adoption
• On-Site Psychiatric/Psychological evaluation and treatment
![Page 55: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/55.jpg)
Use of Psychotropic Medication During Pregnancy
• Weigh risks vs. benefits
• Inform patient of drug’s potential for teratogenic or other adverse effects (Category)
• Consider consequences of untreated psychiatric illness
• Use lowest effective dose
![Page 56: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/56.jpg)
Antidepressants in Pregnancy
• No increase in major malformations– ?cardiac defects with paroxetine
• No increase in long term neurodevelopmental adverse outcomes
• SSRI’s in third trimester– may see withdrawal syndrome in neonate– increase in persistent pulmonary hypertension– no long term residual effects
• Tricyclics relatively safe• MAI inhibitors contraindicated
![Page 57: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/57.jpg)
Benzodiazepines During Pregnancy
• Slight increase in oral clefts
• Possible withdrawal syndrome
• No long term neurodevelopmental adverse effects
![Page 58: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/58.jpg)
Risks of Untreated Depression
• Increase in miscarriage, hypertension and preeclampsia
• Increase in likelihood of relapse to depression with stopping antidepressant medication
• Global IQ negatively associated with duration of depression
• Language development negatively correlated with number of postnatal depressive episodes
![Page 59: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/59.jpg)
![Page 60: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/60.jpg)
![Page 61: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/61.jpg)
![Page 62: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/62.jpg)
![Page 63: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/63.jpg)
Addressing Stigma
• EDUCATE OURSELVES!
– “I don’t believe in methadone!”
– ASAM addressing physician bias• Arizona study -- 96% refusal to treat or
give pain meds• Example of physician opioid addict
![Page 64: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/64.jpg)
Addressing Stigma
• EDUCATE OURSELVES!--continued– Need to educate therapeutic
communities, Minnesota model programs– Need to educate Twelve Step community
• Methadone/buprenorphine as prescribed medications rather than drugs of abuse
• Patients on OMT can work a program of recovery
![Page 65: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/65.jpg)
Addressing Stigma
• Educate service agencies and the general public
– Arizona study -- 66% refused employment or lost job
• Educate patients about the chronic disease concept
– Methadone/buprenorphine as corrective, not curative
• Educate family members
![Page 66: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/66.jpg)
Addressing Stigma
• Publicly funded programs should be mandated to accept patients on OMT
• Private programs should be encouraged to accept patient on OMT
– Great need for residential treatment/halfway houses for women (pregnant or non-pregnant) and their children
![Page 67: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/67.jpg)
Addressing Stigma
• Patients should be encouraged to get involved in advocacy
• Patients need to risk divulging status to treatment providers with support from program staff
![Page 68: Medication Assisted Treatment (MAT) in Pregnant Women Susan F. Neshin, M.D. Medical Director JSAS Healthcare, Inc. Asbury Park, NJ E-mail: jsasmd@aol.com.](https://reader035.fdocuments.in/reader035/viewer/2022062322/56649e235503460f94b10b54/html5/thumbnails/68.jpg)